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Abstract Colorectal cancer (CRC) is the second most
common cancer and second most common cause of
cancer-related deaths in Europe. CRC screening has been
proven to reduce disease-specific mortality and several
European countries employ national screening programmes.
These almost exclusively rely on stool tests, with endoscopy
used as an adjunct in some countries. Computed tomo-
graphic colonography (CTC) is a potential screening test,
with an estimated sensitivity of 88 % for advanced neopla-
sia ≥10 mm. Recent randomised studies have shown that
CTC and colonoscopy have similar yields of advanced
neoplasia per screened invitee, indicating that CTC is po-
tentially viable as a primary screening test. However, the
evidence is not fully elaborated. It is unclear whether CTC
screening is cost-effective and the impact of extracolonic
findings, both medical and economic, remains unknown.
Furthermore, the effect of CTC screening on CRC-related
mortality is unknown, as it is also unknown for colono-
scopy. It is plausible that both techniques could lead to
decreased mortality, as for sigmoidoscopy and gFOBT.
Although radiation exposure is a drawback, this disadvan-
tage may be over-emphasised. In conclusion, the detection
characteristics and acceptability of CTC suggest it is a
viable screening investigation. Implementation will depend
on detection of extracolonic disease and health-economic
impact.
Key Points
￿ Meta-analysis of CTcolonographic screening showed high
sensitivity for advanced neoplasia ≥10mm.
￿ CTC, colonoscopy and sigmoidoscopy screening all have
similar yields for advanced neoplasia.
￿ Good quality information regarding the cost-effectiveness
of CTC screening is lacking.
￿ There is little good quality data regarding the impact of
extracolonic findings.
￿ CTC triage is not clinically effective in first round gFOBT/
FIT positives.
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Introduction
In Europe, colorectal cancer (CRC) is the second most
common cancer, as well as the second most common cause
of death from cancer [1]. In 2008, approximately 432,414
European citizens received a new diagnosis of CRC [2]. The
majority of cancers develop from adenomatous polyps, be-
nign precursors with a relatively long premalignant phase
[3]. Adenomas can vary in size but those ≥10 mm and/or
with ≥25 % of villous histology and/or high-grade dysplasia
have the strongest association with malignancy and are
named advanced adenomas [3]. It is estimated that the
adenoma to carcinoma transition takes at least 10 years
[4]. Several studies have shown that removal of adenomas
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DOI 10.1007/s00330-012-2449-7(e.g. via a CRC screening programme) results in reduced
CRC incidence and CRC-related mortality subsequently, by
interruption of the adenoma-carcinoma pathway [5–7].
Screening programmes can also reduce CRC-related mor-
tality (but have no effect on incidence) by detecting asymp-
tomatic cancers, which tend to be earlier-stage and thus
associated with improved prognosis and survival. The im-
pact of CRC screening is maximised in population-based
programmes, which is more efficient and less costly than
opportunistic screening [8].
Potential CRC screening tests can be generally divided
into two categories: direct and indirect [9]. Stool-based tests
(guaiac Faecal Occult Blood Test, gFOBT; Faecal Immuno-
chemical Test, FIT; Faecal DNA tests) indirectly diagnose
cancers and large adenomas by detecting their by-products
(blood, DNA) in the stool. Such tests are non-invasive, and
in the case of FBOT/FIT simple to perform and relatively
cheap. However, because cancers may not bleed or only
bleed intermittently, they need to be repeated frequently
(e.g. every 2 years). Also, approximately 50 % may be false
positives, leading to unnecessary referrals for subsequent
colonoscopy [10, 11]. Perhaps most importantly, indirect
tests favour cancer detection rather than adenomas, and so
provide less opportunity to impact on cancer incidence.
Direct tests such as flexible sigmoidoscopy, colono-
scopy, CTC directly visualise the target lesion, be it can-
cers or adenomas. Such tests can impact on both cancer
mortality and incidence, and so need repeating only once
per 5–10 years [12, 13]. Compared with indirect tests,
direct tests are more invasive (making them more burden-
some) and costlier.
Newer potential tests include capsule endoscopy, serum-
based markers including serum proteomics, nuclear matrix
proteins and serum DNA testing. None of these have been
sufficiently tested in representative populations.
Effect of screening on CRC-specific mortality
Both gFOBT and flexible sigmoidoscopy screening have
been shown to decrease CRC-related mortality. Several
randomised-controlled trials have shown that biennial
gFOBT screening leads to a subsequent mortality reduction
of 11–21 %, after a median follow-up of 10–13 years (five
to six rounds); overall CRC mortality reduction is approxi-
mately 14 % after 10 years of screening [6, 14–17]. One
large randomised-controlled trial showed that a single flex-
ible sigmoidoscopy performed between 55 and 64 years of
age led to an overall CRC mortality reduction of 31 %
amongst invitees, rising to 42 % in those who attended
[7]. These data prove that removal of benign adenomas
reduces the incidence of subsequent colorectal cancer. It is
therefore plausible that other screening techniques that
reliably identify significant adenomas, namely colonoscopy
and CTC, will also impact on CRC-related mortality. The
magnitude of benefit can only be determined precisely via
large randomised-controlled trials with long-term follow-up.
The NordICC-trial (Nordic Initiative on Colorectal Cancer)
is such a trial that evaluates the effect of colonoscopy
screening on CRC-related mortality with its end-point at
10 years [18]. At the time of writing, we are aware of no
current or planned studies that aim to evaluate the effect of
CTC on CRC-related mortality.
Accuracy
The diagnostic performance of various screening tests is sum-
marised in Table 1. The gFOBT and FIT tests have a per-
patient sensitivity of 11-20 % and 27–48 % respectively for
advanced neoplasia and of 13–38 % and 56–88 % for CRC
[19–23]. Sigmoidoscopy has a sensitivity of approximately
83 % for advanced neoplasia and 58–75 % for CRC [21, 24].
Colonoscopy has a sensitivity of 88 % for all advanced
neoplasia, of 98 % for advanced neoplasia ≥10 mm, and of
95–97 % for CRC [21, 25, 26].
CTC might be a viable alternative since it has an estimated
per-patient sensitivity of 88 % for advanced neoplasia ≥10 mm
inscreeningpopulations[27].Theseestimatesarebasedonthe
aggregated results of five studies (n04,086 average risk par-
ticipants, Table 1) that each evaluated the sensitivity of CTC
relative to colonoscopy in a screening population [21, 26,
28–31]. Three of these studies reported per-patient sensitivity
for advanced neoplasia ≥6 mm, ranging from 84 % to 93 %
[21, 28, 29]. None of the six CRCs were missed by CTC. A
recently published meta-analysis (including both average- and
high-risk subjects)found thatCTC has asensitivityof96% for
CRC, which is comparable to colonoscopy [32].
Attendance and diagnostic yield
The efficacy of a screening programme is not only deter-
mined by diagnostic test accuracy but also by the proportion
of invitees who ultimately attend. For example, the diagnos-
tic yield of CRC screening can be defined as the number of
invitees ultimately found to have advanced neoplasia, per
100 invitees.
Several trials have determined the attendance and subse-
quent diagnostic yield of gFOBT and FIT screening
[33–35]. In most studies, invitees were asked to undergo
more than one test, a procedure that may underestimate
attendance compared with the offer of a single test. In one
of these studies, 23 % of kits that were distributed by the
community drug stores (containing three different stool
tests) were completed and returned [33]. An unrandomised
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offered the choice of gFOBT, FIT, or both, found that 36 %
of invitees participated overall, but relatively more partic-
ipants participated in FIT screening than gFOBT (OR, 1.9;
95 % CI, 1.6–2.2) [35]. The gFOBT and FIT tests had
different diagnostic yields for advanced neoplasia of ap-
proximately 1.4 vs 3.3 per 100 participants respectively
(0.4 vs 1.3 per 100 invitees), but this difference disappeared
after adjustment for differences in baseline characteristics.
In The Netherlands, several population-based screening
trials have been performed over the last decade, compar-
ing attendance and subsequent yield of a first screening
round for gFOBT, FIT and/or flexible sigmoidoscopy [36,
37]. The gFOBT and FIT tests had participation rates of
47 % and 59–60 %, figures that are relatively high compared
with those from other studies [33–35, 38]. Contrasting with
data from previous studies, FIT screening resulted in higher
attendance rates than gFOBT. Thirty percent of invitees for
flexible sigmoidoscopy participated [36]. However, despite
higher participation rates for gFOBT and FIT over flexible
sigmoidoscopy, first round diagnostic yield was only 0.6 and
1.4–1.5 per 100 invitees, compared with 2.2 for sigmoidosco-
py [36, 37].
Previous studies of flexible sigmoidoscopy screening,
performed in Italy and the UK, randomised invitees after
they had indicated that they were interested in participation
or after preselection of average risk subjects by the general
practitioner (in order to increase power) preventing precise
evaluation of attendance rates [7, 39–42]. In the UK study,
38 % of citizens that were contacted participated, while
initially 55 % of subjects responded positively to a mailed
questionnaire that they would like to attend if invited.
As far as we are aware, two randomised controlled trials
have been performed previously, in which the attendance
and diagnostic yield of population-based CTC screening
was compared with colonoscopy [43, 44]. An Australian
trial reported participation rates of 18 % and 16 % for CTC
and colonoscopy respectively, and a subsequent diagnostic
yield (defined as number of participants with advanced
neoplasia) of 9.0 and 8.4 per 100 participants [43]. A Dutch
trial reported participation rates for CTC and colonoscopy of
34 % and 22 % respectively, and a subsequent diagnostic
yield of 6.1 and 8.7 per 100 participants [44]. Ultimately,
enhanced participation for CTC was countered by the great-
er sensitivity of colonoscopy, with the result that the two
tests had similar diagnostic yields for advanced neoplasia of
2.2 and 1.9 per 100 invitees respectively. The Dutch trial
differed in that participants undergoing CTC were only
referred for subsequent colonoscopy if lesions ≥10 mm were
detected (thus increasing positive predictive value); partic-
ipants with lesions of 6–9 mm were offered surveillance
with CTC [44]. Surveillance data are not yet available.
Table 2 compares attendance and yield for differing
s c r e e n i n gt e c h n i q u e sw h e nu s e di nc o m p a r a b l es e t t i n g s
and populations. Whether the differences in compliance
and yield observed in the Dutch trials can be sustained and
extrapolated into future screening rounds is currently un-
known. Two studies reporting the attendance and yield of
subsequent gFOBTscreening rounds found that CRC detec-
tion rate decreased [45, 46]. The first study found that
attendance decreased significantly from 59 % in the first
round to 52 % in the second [45]. Although detection rates
for advanced neoplasia were similar, cancer detection rates
decreased significantly in the second round (from 1.35 to
0.94 per 1,000 screened) [45]. The second study found that
the attendance rate was similar in the first, second and third
rounds of gFOBT screening (55 %, 53 % and 55 %, respec-
tively), but cancer detection decreased from 2.1 per 1,000
participants to 0.7 (first vs third round) [46].
CRC screening guidelines
Recently, the European Union (EU) recommended CRC
screening for men and women aged 50–74 years [8]. Out-
side the EU, several organisations also recommend CRC
Table 1 Accuracy studies CTC screening, per patient sensitivity
Screening studies Number of participants All polyps Adenomas
6-9 mm ≥10 mm 6-9 mm ≥10 mm
Graser et al. [21] 307 86.2 92. 6 90.5 92.0
Johnson et al. [28] 2,249 60.5 80.4 67.4 83.3
Kim et al. [29] 229 60.5 86.7 66.7 90.0
Macari et al. [30] 68 n.a. n.a. n.a. 100
Pickhardt et al. [26, 31] 1,233 n.a. n.a. 86.7 93.8
Data are derived from the meta-analysis on CTC screening by De Haan et al. [27], and do not always correspond directly to the data that were
provided in the original articles because: (1) high-risk participants were excluded from the analyses [28, 29], (2) a different matching algorithm was
used in one study [28], or because additional data (i.e. on accuracy for all polyps) were collected [21, 28, 29].
n.a. not available
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tinal Endoscopy [47], the American Cancer Society, the US
Multi-Society Task Force on Colorectal Cancer, the Amer-
ican College of Radiology [48, 49], the American College of
Gastroenterology [50], and the Asia Pacific Working Group
on Colorectal Cancer [51]. The societal benefits of CRC
screening are clearly widely accepted. However, at this
point in time there is no consensus regarding the preferred
screening investigation or combination of modalities: the
EU only specifies FOBT (gFOBT or FIT) as recommended
screening tests since, at the time the guideline was drafted,
gFOBT was the only test for which a significant decrease in
disease-specific mortality had been demonstrated. Most of
the US guidelines recommend colonoscopy as the first
choice strategy based on superior sensitivity and specificity
for adenomas and cancer (and ignore the fact that a reduc-
tion in disease-specific mortality has not been demonstrated
directly); flexible sigmoidoscopy and/or CTC are alternative
options for those patients who refuse colonoscopy or whose
colonoscopy is incomplete. In Asia, either gFOBT, FIT,
flexible sigmoidoscopy or colonoscopy screening are rec-
ommended. According to EU and Asian guidelines CTC is
not recommended as a screening investigation due to insuf-
ficient evidence of efficacy.
At the time of writing, national CRC screening pro-
grammes for CRC have been implemented in several Euro-
pean countries. For example, in Finland, France and the UK
gFOBT is used as the primary investigation. In Italy both
FIT and flexible sigmoidoscopy are used as primary modal-
ities, while in Poland only colonoscopy is used [8, 52]. The
UK is currently implementing flexible sigmoidoscopy
alongside the gFOBT programme, with a once-once exam-
ination offered at the ages of 55 years [53]. CTC has
supplanted barium enema as the preferred whole-colon ex-
amination in gFOBT-positive patients who cannot undergo
colonoscopy or whose colonoscopy is incomplete, as a
consequence of results from a randomised-controlled trial
of 5,427 symptomatic patients that found CTC significantly
more sensitive than barium enema, with a lesser false-
negative rate.
Is there a role for CTC in population-based CRC
screening?
Advantages of CTC screening
As for colonoscopy, one of the major advantages postulated
for CTC is that it enables visualisation of the entire color-
ectum. Secondly, CTC has the advantage that it detects
advanced neoplasia in an early phase. CTC screening results
in a higher diagnostic yield per 100 invitees than primary
gFOBT and FIT screening, and in a similar yield as sig-
moidoscopy and colonoscopy screening [41, 42, 44]. Be-
cause of enhanced detection characteristics for adenomas
and cancers the inter-test interval for CTC is much longer
than for stool-based tests; e.g once per 5–10 years versus
once per 2 years [13]. Kim et al. [13] recently showed that in
an audit of 1,011 screening participants with a negative
baseline CTC, a single carcinoma occurred during an aver-
age follow-up period of 4.73±1.15 years. Follow-up was
primarily performed by reviewing the electronic medical
records of all participants.
Several comparative non-randomised studies have shown
that CTC is less burdensome than colonoscopy [54, 55]. A
single randomised study of 547 patients performed by Von
Wagner et al. (manuscript recently accepted by Radiology)
found that CTC was more acceptable than colonoscopy and
associated with less physical side-effects, but this was per-
formed in a symptomatic setting (data derived by personal
communication). Although most CTC studies have utilised
full cathartic bowel cleansing, non-cathartic preparations are
increasingly popular and are expected to enhance compli-
ance. Iodine is already used to tag residual stool with the
aim of facilitating radiological interpretation, and this ap-
proach can be extrapolated into a non-cathartic preparation,
Table 2 CRC screening
techniques: overview of sensi-
tivity, (Dutch) attendance and
diagnostic yield of a first round
of population-based screening,
and CRC-related mortality
reduction
aAttendance defined as number
of invitees that completed the
screening procedure
bAdvanced neoplasia ≥6m m
gFOBT FIT Sigmoidoscopy Colonoscopy CTC
Sensitivity
- advanced
neoplasia
11-20 %
[19–23]
27-48 %
[19–23]
83 % [21, 24]8 8 % [ 21, 25, 26] 84-93 %
[21, 26–32]
b
- CRC 13-38 % 56-88 % 58-75 % 95-97 % 96-100 %
Attendance (%)
a 47 %
[36, 37]
59-60 %
[36, 37]
30 % [36]2 2 % [ 44]3 4 % [ 44]
Yield advanced
neoplasia
- per 100 exams 1.2 [36, 37] 2.4-2.5
[36, 37]
7.3 [36] 8.7 [44] 6.1 [44]
- per 100 invitees 0.6 1.4-1.5 2.2 1.9 2.1
Mortality reduction 14 % [6] Unknown 32 % [7] Unknown Unknown
1498 Eur Radiol (2012) 22:1495–1503decreasing the volume ingested orally. A disadvantage of
most iodinated contrast agents is that they induce diarrhoea
because most agents are hyperosmotic. This non-cathartic
bowel preparation has recently been shown in a randomised-
controlled design to be less burdensome than the alternative
of 2 l of laxatives and 2 l of clear fluids required for
colonoscopy [56]. However, the same investigators also
found that increased diarrhoea was perceived as more
burdensome by CTC participants [56]. Invitees were also
asked—before they underwent the allocated screening
procedure—whether they anticipated the procedure would
be burdensome: 36 % of colonoscopy invitees anticipated a
“rather” or “extremely” burdensome experience compared
with only 9 % of CTC invitees. Ultimately, 21 % of CTC
participants indicated that the experience was “worse” than
expected, compared with 12 % of colonoscopy participants.
These findings suggest that CTC invitees underestimate the
burden of CTC (e.g. diarrhoea and abdominal pain) relative
to colonoscopy. The differences in perceived burden of
the entire screening procedure were small (mean score
on five-point Likertscale 1.8 incolonoscopy vs2.0 inCTCl,
P<0.001), and did not result in a significantly different pro-
portion of participants that indicated they would be willing to
participate in a future screening round. Other bowel prepara-
tion schemes with less iodine may result in a less burdensome
procedure.
The relatively low risk of serious adverse events associ-
ated with CTC is frequently cited as an advantage compared
with colonoscopy screening, which has a complication risk
of 0.1-0.3 % [57–59]. However, while this holds true for the
examinations in isolation, the correct approach is to consider
the diagnostic pathway as a whole. Colonoscopic complica-
tions precipitated by a positive CTC result must be included
and accounted for as part of the diagnostic trajectory for
screening CTC. In the Dutch trial, the prevalence of post-
polypectomy bleeding was non-significantly different for
CTC (0.3 % of participants) and colonoscopy (0.2 % of
participants) [44].
Whether the visualisation of extracolonic structures and
consequent detection of potential pathology is an advantage
or disadvantage is frequently debated and remains unclear. It
is clear, however, that potential screenees regard this aspect
of CTC as attractive, intriguing and a distinct advantage
over all other competing tests [60]. In a screening popula-
tion, the prevalence of (potentially) important findings that
precipitate additional diagnostic follow-up testing ranges
from 4.5 to 11 % [30, 43, 61, 62]. One audit of 10,286
participants undergoing CTC screening found extracolonic
(non-colorectal) cancer in 36 (0.35 %) participants; renal
cell carcinoma, lung adenocarcinoma and non-Hodgkin
lymphoma were most common [63]. However, the majority
of potentially important findings ultimately emerge as clin-
ically unimportant after follow-up testing, and therefore
have the potential to cause anxiety, morbidity (and even
mortality) for no clinical benefit. Furthermore, the incre-
mental costs of diagnostic follow-up tests, including surgery
and additional clinic visits, etc., may be substantial, averag-
ing from €20 to €25 per participant overall [61, 62]. It is
possible that early detection of important extracolonic find-
ings might ultimately lead to lower costs and decreased
mortality in the long run, but these data are currently un-
available and would require randomised trials with tens of
thousands of participants. Currently, the only data available
arise from modelling the costs and consequences of extrac-
olonic detections using currently available research. For
example, one approach is to screen only for intracolonic
lesions, aortic aneurysms and extracolonic cancers [64,
65]. At the time of writing, it is uncertain whether this is
feasible; in some countries, it is hard to imagine that radiol-
ogists will be allowed legally to “close their eyes” to certain
categories of findings potentially revealed by CTC.
Disadvantages of CTC screening
When CTC is used for screening—as for positive stool tests
and flexible sigmoidoscopy—there is a need for subsequent
testing in positive patients who have a potential lesion large
enough to trigger subsequent colonoscopy. In an non-
randomised USA study that evaluated the diagnostic yield
per 100 participants for colonoscopy and CTC, 7.9 % of
participants having CTC were referred for subsequent colo-
noscopy [57]. Participants with lesions of 6–9 mm were
offered the choice of colonoscopy or surveillance CTC.
Within the Dutch screening trial, 8.6 % of CTC participants
were referred for colonoscopy as a consequence of lesions
≥10 mm. However, if a referral threshold of ≥6 mm were
used, 16.7 % of participants having CTC would have been
referred for subsequent colonoscopy.
Exposure to ionizing radiation may provoke radiation-
induced cancers, but this potential disadvantage needs to be
balanced against potential gains. Gonzales et al. [66] esti-
mated that a 5-yearly CTC screening program would pre-
vent the development of 24 CRCs for every radiation-
induced cancer, based on an estimated mean effective dose
of 8 mSv for women and 7 mSv for men. In fact, the dose
conveyed by screening CTC averages 4 mSv [67].
Most previous cost-effectiveness models of population-
based CTC screening programmes estimate that CTC is less
cost-effective than alternative methods [64, 68–73]. Accord-
ing to some of these models, CTC screening could be more
cost-effective than colonoscopy if the unit cost per CTC falls
tolessthan60-72%oftheunitcostsforcolonoscopy[64,68],
if attendance for CTC is ≥25 % higher than colonoscopy [69]
or a combination of both that offers a net-benefit [70]. How-
ever, the precise unit cost of CTC when employed within
population-based CRC screening programmes is largely
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question. Existing estimates (calculated in previous cost-
effectiveness analyses) are based on unit costs ranging from
€346 to €594 for abdominal and/or pelvic CTor colonoscopy,
oronunspecifiedassumptionsrelatedtocosts[64,65,68–73].
Increasedefficienciesthatare likelytoaccompanythedeploy-
ment of CTC in a screening programme would probably
diminish the unit cost for CTC when used in this setting,
compared with unit costs in symptomatic patients. Ultimately,
the key-metric required by health policy makers will be the
cost-per-cancer detectedand the cost-per-significant-adenoma
detected per 100 subjects invited for screening, which allows
direct cost-comparisons between competing screening modal-
ities. The costs, diagnoses and consequences of screening
should be collected prospectively as part of a randomised
controlled trial (or established screening programme) so that
the cost-effectiveness model is populated with reliable data
rather than test characteristics and costs estimated from the
literature, which may beinaccurateorderived fromhealthcare
settings that are not generalizable to the setting in question.
Logistics
Before CTC is implemented as the primary screening inves-
tigation, sufficient CT system capacity should be available.
Assuming that there is limited free time available on hospi-
tal CT systems currently, this would likely require large-
scale investment to increase available screening capacity.
One potential approach might utilise mobile CTC units
similar to those that are used currently for breast cancer
screening in several countries, including the UK and The
Netherlands; such dedicated units are likely efficient and
may increase attendance due to the convenience of proxim-
ity. It is clear that sufficient, adequately trained CTC readers
are needed; on average, inexperienced readers need training
with at least 175 individual cases before they reach an
acceptable sensitivity and specificity for lesions of 6 mm
and larger [74]. One alternative possibility is to train radio-
graphic technicians to interpret CTC, since they are less
expensive than radiologists [75]. Such an approach would
also lower the unit cost of CTC. Previously, several studies
in clinical cohorts had indicated that technologists may be
adequate CTC readers, as they reached a diagnostic accura-
cy that was comparable to the radiologist [76–78]. A recent
study performed within a population-based CTC screening
study showed that a reading strategy of two technologists
with or without consensus would result in a comparable
diagnostic yield for advanced neoplasia compared with a
reading strategy of one radiologist [79].
Another alternative could be to use computer-aided de-
tection (CAD) as second reader, subsequent to the radiol-
ogist’s interpretation. This strategy has shown to result in
significantly higher sensitivity for lesions of ≥6 mm and
although specificity inevitable decreases, it does not do so
significantly [75, 80]. Additionally, CAD might be used as
the primary CTC reader (i.e. in advance of any radiologist
interpretation), followed by a radiologist evaluation restrict-
ed to the CAD marks. An Italian study of FOBT positives
recently showed that such a reading detected 11 of 13
colorectal carcinomas. If the evaluation of CAD findings
was followed by evaluation of the 2D images, this resulted
in a sensitivity of 89 % for advanced adenomas, which was
comparable to double primary 2D read followed by second-
ary CAD read [81].
CTC as a triage test following positive FOBT?
As positive stool tests have a relatively limited positive
predictive value for CRC, it has been suggested that CTC
could be used as an intermediate test, triaging FOBT pos-
itives for colonoscopy. CTC has a per-patient sensitivity of
93 % for adenomas ≥6 mm and of 95 % for advanced
neoplasia ≥10 mm and CRC, in FOBT positives (using
FIT or gFOBT) [82]. A previous study performed in 302
FOBT-positive individuals found that CTC would prevent a
subsequent colonoscopy in only 28 % of cases, while
lesions ≥10 mm would have been missed in 2 % [83]. Given
the relatively high prevalence of abnormality in patients
who are FOBT-positive, it is unlikely that CTC is a clini-
cally effective or cost-effective triage method in first-round
FOBT screening. CTC may have a role in subsequent
rounds when the prevalence of abnormality may be
expected to decrease, or where newer stool tests are
employed that have greater sensitivity but proportionally
less specificity when compared with gFOBT.
Conclusion
Screening for colorectal cancer using CTC as a primary
investigation is feasible; the detection characteristics of
CTC in this context are increasingly well-established and
compliance seems to be increased. These factors lead to a
similar yield of advanced neoplasia for CTC compared with
colonoscopy and flexible sigmoidoscopy, and higher yields
than gFOBT and FIT. Therefore, the viability of CTC as a
primary screening investigation is likely to turn on other
factors, such as cost-effectiveness and whether the ability to
detect extracolonic disease (impossible with alternative
investigations) is ultimately beneficial or not. Whether there
is a need to demonstrate a direct reduction in disease-
specific mortality is debatable given that detection charac-
teristics of CTC for cancers and adenomas are well-defined.
However, the CTC community should be aware that the lack
of large-scale implementation pilots, including an evaluation
1500 Eur Radiol (2012) 22:1495–1503of effect on disease-specific mortality, remains an obstacle for
health-policy makers shaping population-based CTC screen-
ing in Europe in the future.
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